Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

Anti-PD-1 therapy yields objective clinical responses in 30–40% of advanced melanoma patients. Since most patients do not respond, predictive biomarkers to guide treatment selection are needed. We hypothesize that MHC-I/II expression is required for tumour antigen presentation and may predict anti-P...

Full description

Saved in:

Bibliographic Details
Published in:	Nature communications Vol. 7; no. 1; pp. 10582 - 10
Main Authors:	Johnson, Douglas B., Estrada, Monica V., Salgado, Roberto, Sanchez, Violeta, Doxie, Deon B., Opalenik, Susan R., Vilgelm, Anna E., Feld, Emily, Johnson, Adam S., Greenplate, Allison R., Sanders, Melinda E., Lovly, Christine M., Frederick, Dennie T., Kelley, Mark C., Richmond, Ann, Irish, Jonathan M., Shyr, Yu, Sullivan, Ryan J., Puzanov, Igor, Sosman, Jeffrey A., Balko, Justin M.
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 29.01.2016 Nature Publishing Group Nature Portfolio
Subjects:	13/106 13/31 13/51 13/95 38/39 631/250/21/324 64/60 692/308 692/699/67/1059 692/699/67/1813/1634 82/51 Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal, Humanized Cell Line, Tumor Gene Expression Regulation, Neoplastic - physiology Genes, MHC Class II - genetics Genotype Humanities and Social Sciences Humans Melanoma Melanoma - genetics Melanoma - metabolism multidisciplinary Nivolumab Programmed Cell Death 1 Receptor - antagonists & inhibitors RNA, Messenger - genetics RNA, Messenger - metabolism Science Science (multidisciplinary) Tumors
ISSN:	2041-1723, 2041-1723
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!